Abstract
Respiratory diseases are frequently caused by immature respiratory and cardiovascular systems in the premature newborn and by adaptation mechanisms related to asphyxia and congenital malformations in the full-term newborn. Perinatal infections affect both premature and full-term newborns. Respiratory diseases can be classified as those caused by (a) perinatal asphyxia, (b) related to immaturity and lung liquid reabsorption, (c) related to lung circulation, (d) caused by infections in the newborn, and (e) caused by congenital alterations of the airway and lungs. The clinical picture is usually referred to as respiratory distress syndrome characterized by the presence of tachypnea, retraction, grunting, cyanosis, and apnea, whether of a respiratory or nonrespiratory source. A detailed perinatal anamnesis based on risk factors, an exhaustive physical examination, and complementary laboratory testing are essential for determining a precise diagnosis. Adequate management of each condition depends on the understanding of the underlying physiopathological mechanisms. Respiratory diseases increase mortality and morbidity rates in the newborn. The change from intrauterine breathing through the placenta to the external pulmonary breathing grants a unique feature to these problems, which are, to a great extent, caused by the alteration of the cardiopulmonary adaptation. In premature newborns, immature respiratory and cardiovascular systems are the most important cause of respiratory diseases. For the term newborn, adaptation mechanisms are mainly altered by asphyxia and congenital malformations. Perinatal infections affect both term and preterm newborns and are a frequent cause of respiratory problems.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Sources
Bahadue FL, Soll R. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database Syst Rev. 2012;11:CD001456.
Committee on Fetus and Newborn; American Academy of Pediatrics. Respiratory support in preterm infants at birth. Pediatrics. 2014;133:171–4.
Fehlmann E, Tapia JL, Fernández R, Bancalari A, Fabres J, D’Apremont I, García-Zattera MJ, Grandi C, Ceriani Cernadas JM, Grupo Colaborativo Neocosur. Impacto del síndrome de dificultad respiratoria en recién naci-dos de muy bajo peso de nacimiento: estudio multicéntrico sudamericano. Arch Argent Pediatr. 2010;108(5):393–400.
Finer NN, Carlo WA, Walsh MC, et al. SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network. Early CPAP versus surfactant in extremely preterm infants. N Engl J Med. 2010;362(21):1970–9.
González A, Sosenko Y, Chandar J y cols. Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000g or less. J Pediatr. 1996;128:470.
González A, Fabres J, D’Apremont I, Urcelay G, Avaca M, Gandolfi C, Kattan J. Randomized controlled trial of early compared with delayed use of inhaled nitric oxide in newborns with a moderate respiratory failure and pulmonary hypertension. J Perinatol. 2010;30(6):420–4.
Grupo Colaborativo Neocosur. Very low birth weight infants outcome in 11 South American NICU’s. J Perinatol. 2002;22:2–7.
Hahn S, Choi HJ, Soll R, Dargaville PA. Lung lavage for meconium aspiration syndrome in newborn infants. Cochrane Database Syst Rev. 2013;4:CD003486.
Halliday HL, Sweet D. Endotracheal intubation at birth for preventing morbidity and mortality in vigorous, meconium-stained infants born at term. Cochrane Library. 2003;1:CD000500.
Henderson-Smart DJ, Steer PA. Caffeine versus theophylline for apnea in preterm infants. Cochrane Database Syst Rev. 2010;1:CD000273.
Ministerio de Salud Chile. Guía Clínica AUGE, Síndrome de dificultad respiratoria del recién nacido. Garantías Explícitas en Salud. Noviembre 2011. www.supersalud.gob.cl.
Murphy KE, Hannah ME, Willan AR, et al. MACS Collaborative Group. Multiple courses of antenatal corticosteroids for preterm birth (MACS): a randomised controlled trial. Lancet. 2008;372:2143–51.
NIH Consensus Conference. Effect of corticosteroids for fetal maturation on perinatal outcomes. JAMA. 1995;273(5):413–18.
Porta NF, Steinhorn RH. Pulmonary vasodilator therapy in the NICU: inhaled nitric oxide, sildenafil, and other pulmonary vasodilating agents. Clin Perinatol. 2012;39(1):149–64.
Rojas-Reyes MX, Morley CJ, Soll R. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2012;3:CD000510.
Tapia JL, Urzúa S, Bancalari A, Meritano J, Torres G, Fabres J, Toro CA, Rivera F, Céspedes E, Burgos JF, Mariani G, Roldán L, Silvera F, González A, Domínguez A. Randomized trial of early bubble continuous positive airway pressure (CPAP) for very low birth weight infants. J Pediatr. 2012;165:75–80.
Vento M. Oxygen supplementation in the neonatal period: changing the paradigm. Neonatology. 2014;105:323–31.
Weisman LE, Hansen TN. Contemporary diagnosis and management of: neonatal respiratory diseases. 3rd ed. Newton: Handbooks in Health Care; 2003.
Weisz DE, McNamara PJ. Patent ductus arteriosus ligation and adverse outcomes: causality or bias? J Clin Neonatol. 2014;3(2):67–75.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Tapia Illanes, J.L., Toso Milos, P., Kattan Said, J. (2020). Respiratory Diseases in the Newborn. In: Bertrand, P., Sánchez, I. (eds) Pediatric Respiratory Diseases. Springer, Cham. https://doi.org/10.1007/978-3-030-26961-6_36
Download citation
DOI: https://doi.org/10.1007/978-3-030-26961-6_36
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-26960-9
Online ISBN: 978-3-030-26961-6
eBook Packages: MedicineMedicine (R0)